ArticleScientific reports2026
Investigating Escherichia coli Colicin E9 immunity protein interactions with DNA gyrase of Pseudomonas aeruginosa: advanced computational approach for developing novel antimicrobial strategies.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Protein-protein interactions (PPIs) are essential to numerous cellular processes, making a thorough investigation of these interactions crucial for a deeper understanding of molecular mechanisms. This research initiative aims to elucidate the complex relationship between the Colicin E9 immunity protein from Escherichia coli (E. coli) and DNA gyrase from Pseudomonas aeruginosa, a significant target for antimicrobial strategies. By inhibiting DNA gyrase, the immunity protein Colicin E9, produced by E. coli, allows the host to generate a protective protein that lowers the risk of self-toxicity from this interaction. Understanding this relationship can aid the development of antibacterial strategies to combat resistant infections. Molecular docking, molecular dynamics (MD) simulations, and binding energy analyses were integral to the computational approach used in this study. MD simulations were employed to assess the stability and dynamics of the protein complex after docking was conducted using ClusPro and LightDock. The MM-GBSA method was used to evaluate binding free energies and to characterise structural features through hydrogen-bond analysis to uncover key stabilising interactions. Several important residues were identified that help stabilise the interface between the two proteins: HIS40, MET27, LYS105, GLU44, ASP47, and three others. The ClusPro complex displayed impressive interactions, featuring between six and ten hydrogen bonds along with a binding free energy of ΔG = -3.88 kcal/mol, indicating a strong protein interaction. Despite some variations, both complexes maintained stable interfaces throughout the MD simulations, and DNA gyrase retained its structural integrity. This study concludes that the protein complex formed between the Colicin E9 immunity protein and DNA gyrase is stable, paving the way for future experiments and the development of new antimicrobial agents targeting DNA gyrase in P. aeruginosa infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.